CytomX Therapeutics (CTMX) EBIT Margin (2014 - 2026)

CytomX Therapeutics has reported EBIT Margin for 13 years, with the latest figure at 191.77% in Q1 2026.

• For the quarter ending Q1 2026, EBIT Margin fell 23620.0% year-over-year to 191.77%; the trailing twelve-month figure through Mar 2026 stood at 129.12% (down 15349.0% YoY), and the FY2025 full-year result was 4.72%, down 2282.0% from the prior year.
• EBIT Margin for Q1 2026 stood at 191.77%, up from 1382.5% in the prior quarter.
• The five-year high for EBIT Margin was 46.41% in Q4 2024, with the low at 1382.5% in Q4 2025.
• Historically, EBIT Margin has averaged 157.55% across 5 years, with a median of 24.06% in 2023.
• Annual changes were most pronounced in 2023 — EBIT Margin jumped 33061 bps — and 2025, when it slumped 142891 bps.
• CytomX Therapeutics' EBIT Margin stood at 47.25% in 2022, then surged by 95 bps to 2.28% in 2023, then soared by 2138 bps to 46.41% in 2024, then plunged by 3079 bps to 1382.5% in 2025, then surged by 86 bps to 191.77% in 2026.
• The last three EBIT Margin figures came in at 191.77% (Q1 2026), 1382.5% (Q4 2025), and 264.43% (Q3 2025), per Business Quant data.